Particulars (Rs. In cr) | Q2FY25 | Q2FY24 | YoY (%) | Q1FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 1371.00 | 1031.00 | 33.00% | 1363.00 | 1.00% |
EBITDA | 868.00 | 488.00 | 78.00% | 853.00 | 2.00% |
EBITDA Margin (%) | 60.49% | 45.99% | 1450 bps | 60.45% | 4 bps |
PAT | 676.00 | 369.00 | 83.00% | 669.00 | 1.00% |
EPS (Rs.) | 37.81 | 20.60 | 84.00% | 37.32 | 1.00% |
Source: Company Filings; stockaxis Research
Q2FY25 Result Highlights
Natco Pharma delivered robust financial performance for the quarter ended Q2FY25.
Consolidated net sales rose 33% YoY to Rs.1371 cr led by sustained momentum in the
export business. Gross Margin expanded 796 bps to 87.6% due to the profit share
of gRevlimid. Consolidated EBITDA surged 78% YoY to Rs.868cr while EBITDA Margins
expanded significantly by 1450 bps YoY and stood at 60.49%. PAT soared 83% YoY to
Rs. 677 cr boosted by higher other income (+117% YoY).
Domestic formulations revenues growth remained flat YoY to Rs.102 cr. Export formulations revenue was up 53% YoY (flat QoQ) to Rs.1211 cr driven by higher sales and profit share of gRevlimid and traction in subsidiaries. The Crop Sciences business declined 75% YoY to Rs. 14.1cr in Q2FY25 due to provisions for sales returns and discounts. The API business declined 36% YoY (-+27% QoQ) to Rs.49.6 cr impacted by higher captive consumption.
Key Conference call takeaways
Guidance: (i) Management has pegged FY25 revenue growth guidance at 15–20%,
(ii) PAT growth is expected to be 20% for FY25.
Key Takeaways:
Product Updates
Acquisition
Subsidiary revenue:
Crop Health Science segment
Cash and Bank
R&D
Concerns
Outlook & Future Strategy
Other Key Points
Natco Pharma posted stellar earnings growth for the quarter ended Q2FY25. The company is focusing on expanding its presence in both domestic and international markets. Natco’s focus on strengthening the core business is bearing fruit, evident from steady India and Agrochem ramp-up (25% growth potential). Management expects a significant improvement in its market share in gRevlimid, which will likely touch ~33% in H2FY26. The company has a strong pipeline of FTF opportunities that includes assets such as Semaglutide, Olaparib, and Ibrutinib, Carfilzomib (10mg), Bosentan (32mg), which should drive growth in the long term while the company also aims to file 2–3 limited competition products in the US every year. We welcome the R&D ramp-up (from 8% to 10% of revenue) given Natco’s strength in complex generics. The strong Balance Sheet provides ample scope to pursue inorganic opportunities. With the base business recovering and Natco pursuing complex opportunities with gRevlimid, long term outlook appears promising. Management also sounds confident and has guided for 15-20% sales growth and 20% PAT growth in FY25 thus reaffirming its bullish stance. At a CMP of Rs.1364, the stock is trading at 15x FY26E. We maintain a HOLD rating on the stock.
Particulars (Rs. In cr) | Q2FY25 | Q2FY24 | YoY (%) | Q1FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from operations | 1371.00 | 1031.00 | 33.00% | 1363.00 | 1.00% |
Other Income | 64.00 | 29.00 | 121.00% | 48.00 | 33.00% |
Total Income | 1435.00 | 1061.00 | 35.00% | 1411.00 | 2.00% |
Cost of goods sold | 178.00 | 216.00 | -18.00% | 180.00 | -1.00% |
Gross Profit | 1257.00 | 845.00 | 49.00% | 1231.00 | 2.00% |
Gross Margin (%) | 87.60% | 79.64% | 796 bps | 87.24% | 36 bps |
Employee Benefit Expenses | 151.00 | 122.00 | 24.00% | 142.00 | 6.00% |
Other Expenses | 238.00 | 235.00 | 1.00% | 236.00 | 1.00% |
EBITDA | 868.00 | 488.00 | 78.00% | 853.00 | 2.00% |
EBITDA Margin (%) | 60.49% | 45.99% | 1450 bps | 60.45% | 4 bps |
Depreciation expenses | 46.00 | 44.00 | 5.00% | 44.00 | 5.00% |
EBIT | 822.00 | 444.00 | 85.00% | 809.00 | 2.00% |
Finance cost | 4.00 | 4.00 | 0.00% | 5.00 | -20.00% |
PBT | 818.00 | 440.00 | 86.00% | 804.00 | 2.00% |
Tax expenses | 142.00 | 71.00 | 100.00% | 135.00 | 5.00% |
PAT | 676.00 | 369.00 | 83.00% | 669.00 | 1.00% |
EPS (Rs.) | 37.81 | 20.60 | 84.00% | 37.32 | 1.00% |